



Mylan Prepared To Produce Tamiflu in Response to Potential Global Public Health Need

PITTSBURGH, Oct. 20 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today confirmed that the Company is prepared to produce significant volumes of Tamiflu, a pharmaceutical product produced by Roche Holdings AG. Tamiflu, which is used to treat flu symptoms, is in high demand based on global concerns over a potential avian flu pandemic. Mylan was contacted by United States Senator Charles Schumer, D-N.Y., and the company intends to immediately begin working with political leaders, the United States Food and Drug Administration and Roche to respond to this global health situation.

Robert J. Coury, Mylan's Vice Chairman and Chief Executive Officer. "Mylan is uniquely positioned to respond to this need for increased production of Tamiflu. We have always structured our manufacturing capacity to be able to rapidly respond to urgent needs such as this one and we stand ready to contribute to the production of this important medication."

About Mylan Laboratories

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

This press release includes statements that constitute "forward-looking statements," including with regard to production of Tamiflu. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: risks inherent in licensing negotiations; unexpected regulatory or other delays; the possible negative effects of any interruption or delay in the manufacture of the product; dependence on third parties for an adequate supply of the active ingredient; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

SOURCE Mylan Laboratories Inc.

10/20/2005

CONTACT: Patrick Fitzgerald, Public Relations, or Kris King, Investor Relations, both of Mylan Laboratories Inc., 1-724-514-1800

Web site: <http://www.mylan.com>

(MYL)